EK

Elavumkudy Krishnan Kutty Vijayan

Active Director Director DIN 09760139
DIN 09760139 First appointment Oct 2022 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Oct 2022
Shareholding value β€’β€’β€’β€’ Premium profile

About Elavumkudy Krishnan Kutty Vijayan

Data last updated:

Elavumkudy Krishnan Kutty Vijayan is a Director at Liaga Pharmaceuticals Private Limited (since 2022). The company operates in Pharma.

DIN 09760139
Primary Designation Director
Industry Pharma
First Appointment 10 Oct 2022
Oldest Company Age 4 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director10 Oct 20222022Active

Board colleagues of Elavumkudy Krishnan Kutty Vijayan

Directorship timeline

Open interactive timeline →
Liaga Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Elavumkudy Krishnan Kutty Vijayan

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Elavumkudy Krishnan Kutty Vijayan

Elavumkudy Krishnan Kutty Vijayan currently holds 1 directorship: Liaga Pharmaceuticals Private Limited (Director, since 10 Oct 2022).

Elavumkudy Krishnan Kutty Vijayan was first appointed on 10 Oct 2022 as Director at Liaga Pharmaceuticals Private Limited.

The current boards of Elavumkudy Krishnan Kutty Vijayan's companies include Darshan Sharma (Liaga Pharmaceuticals Private Limited), Ramachandran Manalmaril Krishnan (Liaga Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available